Liquid crystal nanoparticle platform for increased efficacy of cationic antimicrobials against biofilm infections
Date
2022
Authors
Thorn, C.R.
Kopecki, Z.
Wignall, A.
Kral, A.
Prestidge, C.A.
Thomas, N.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Nanomedicine: Nanotechnology, Biology, and Medicine, 2022; 42(102536)
Statement of Responsibility
Conference Name
Abstract
Bacterial biofilm infections tolerate high concentrations of antibiotics and are insidiously challenging to treat. Liquid crystal nanoparticles (LCNPs) advance the efficacy of tobramycin in biofilm-related infections by increasing the penetration of antibiotics across the biofilm matrix. Herewith, we develop the LCNPs as a platform technology, demonstrating that the LCNPs can increase the efficacy of two antibiotic classes (i.e. aminoglycosides and colistin) in P. aeruginosa biofilm infections. In C. elegans, the LCNPs potentiated the antimicrobial effect and significantly improved the survival of the nematodes. In mice with a full-thickness excisional wound, LCNPs were non-toxic and did not impair wound repair. Compared to the unformulated antibiotic treatment, tobramycin-LCNPs reduced the chronic bacterial load by 100-fold in the wound. This was also emulated in an ex vivo P. aeruginosa porcine wound infection model. The LCNPs represent a versatile platform technology that improves the efficacy of cationic antibiotics against biofilm infections utilizing multiple administration routes.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2022 Elsevier